Remedy of human coroviruse infection with genetic nanocomposit drug

The effect of genetical nanocomposit drug with cell imunity level on human coronavirus (COVID-19)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200321046828N1

Enrollment

Registered

2020-03-26

Start date

2020-03-22

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease and respiratory of the Corona virus. Coronavirus infection

Interventions

Intervention 1: Control group 1: Positive people with corona virus infection after laboratory tests are classified according to expert diagnosis and based on the patient's symptoms and history as well

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Infection with coronavirus

Exclusion criteria

Exclusion criteria: People with multiple problems Cancer Critical physical condition

Design outcomes

Primary

Measure	Time frame
The treatment of patients with corona infection. In healthy subjects the CT image of the lungs signs an improvement of the corona contamination. Timepoint: At the beginning of the test, positive people are determined based on who tests and then the severity of disease is classified through fever and CT-pulmonary image. Then, after 8-10, the initial cases including fever and CT lungs, as well as general individuals, were analyzed. Method of measurement: CT scan.;Fever. Timepoint: At the beginning of the test, then 8 - 10 days after taking the new drug and ensuring efficacy. Method of measurement: Thermometers.	—

Measure

Time frame

The treatment of patients with corona infection. In healthy subjects the CT image of the lungs signs an improvement of the corona contamination. Timepoint: At the beginning of the test, positive people are determined based on who tests and then the severity of disease is classified through fever and CT-pulmonary image. Then, after 8-10, the initial cases including fever and CT lungs, as well as general individuals, were analyzed. Method of measurement: CT scan.;Fever. Timepoint: At the beginning of the test, then 8 - 10 days after taking the new drug and ensuring efficacy. Method of measurement: Thermometers.

—

Secondary

Measure	Time frame
General condition of people and vitality after treatment. Timepoint: After 8-12 days after the start of treatment. Method of measurement: Examination and explanation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mahdi Khozaei

Islamic Azad University

mahdi_khozaei@yahoo.com+98 31 3267 3139

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026